PDCD1 and neoplasm: Similar to responses observed in other s.c. tumor models, treatment with the anti‐RANKL/PD‐1 BsAb (100 or 200 μg) or combination of anti‐RANKL plus anti‐PD‐1 antibodies significantly controlled AT3‐OVAdim established tumor growth in WT mice compared with anti‐PD‐1 monotherapy (****P < 0.0001; Figure 5).